更新于：2024-11-15
Pinaverium bromide
匹维溴铵
更新于：2024-11-15
概要
基本信息
结构
分子式C26H41Br2NO4 |
InChIKeyIKGXLCMLVINENI-UHFFFAOYSA-M |
CAS号53251-94-8 |
关联
18
项与 匹维溴铵 相关的临床试验匹维溴铵片在中国健康受试者中餐后状态下的单剂量、随机、开放、四周期、两序列、完全重复交叉的生物等效性正式试验
匹维溴铵片在健康人群中的生物等效性试验
匹维溴铵片在健康受试者中随机、开放、单剂量、两制剂、重复交叉对照空腹及餐后状态下的生物等效性研究
100 项与 匹维溴铵 相关的临床结果
登录后查看更多信息
100 项与 匹维溴铵 相关的转化医学
登录后查看更多信息
100 项与 匹维溴铵 相关的专利（医药）
登录后查看更多信息
165
项与 匹维溴铵 相关的文献（医药）2024-08-28IUCrData
Article
作者: Rousselin, Yoann ; Clavel, Alexandre
The structure of pinaverium bromide (systematic name: 4-[(2-bromo-4,5-dimethoxyphenyl)methyl]-4-{2-[2-(6,6-dimethyl-2-bicyclo[3.1.1]heptanyl)ethoxy]ethyl}morpholin-4-ium bromide; C26H41Br2NO4), was determined at 110 K. It has monoclinic (P21) symmetry. It is of interest with respect to its anti-inflammatory properties. The asymmetric unit contains two independent molecules, one of which exhibits disorder of the bicyclo terminal group (occupancy factors: 0.78 and 0.22).
2024-06-01ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY
Acute exposure and biomarkers assessment in rainbow trout exposed to selected pharmaceuticals
Article
作者: André, C ; Gagné, F ; Auclair, J
Pharmaceuticals released from municipal effluents discharges pose a risk to aquatic organisms. The toxicity of 5 pharmaceuticals with distinct therapeutic actions were assessed in rainbow trout: olanzapine (antipsychotic), erythromycin (antibiotic), mycophenoate (immunosuppression), pinaverium (anti-inflammatory) and trazodone (sedative). Juveniles were exposed to these drugs for 96 h at concentrations between 64 µg/L up to 40 mg/L to reach lethality. Survival was determined and a suite of biomarkers was analyzed for drug biotransformation, oxidative stress/damage and metabolic activity at sublethal concentrations. The data revealed the following toxicity: olanzapine >trazodone>mycophenolate>pinaverium∼erythromycin based on mortality. The data also revealed that toxicity was associated to mass, pKa and hydrophobicity and the following sublethal effects: GST, LPO and DNA strand breaks. Pharmaceuticals with lower molecular weight, physiological pKa, moderate hydrophobicity, low biotransformation and DNA strand breaks were generally more toxic to fish. However, this should be considered as a general guide in identifying toxic pharmaceuticals in non-target organisms.
2024-03-01JGH open : an open access journal of gastroenterology and hepatology
Efficacy and safety of pinaverium bromide as an add‐on therapy in refractory dyspepsia: A randomized controlled trial
Article
作者: Kijdamrongthum, Phuripong ; Thinrungroj, Nithi ; Kamolsripat, Thansita ; Praisontarangkul, Ong-Ard ; Chitapanarux, Taned ; Pojchamarnwiputh, Suwalee ; Thongsawat, Satawat ; Pinyopornpanish, Kanokwan ; Leerapun, Apinya
Abstract:
Background and Aim:
Functional dyspepsia (FD) remains a therapeutic challenge, and the efficacy of antispasmodic agents as adjunctive therapy is not well established. This study aimed to evaluate the efficacy and safety of pinaverium bromide added to omeprazole in treating refractory FD.
Methods:
We conducted a randomized, placebo‐controlled trial in patients with refractory dyspepsia. Participants were randomly assigned to receive pinaverium (50 mg, 3 times/day, n = 36) or placebo (n = 36) in addition to omeprazole for 8 weeks. The primary endpoint was the responder rate for adequate relief. Secondary outcomes included the Global Overall Symptom Scale (GOSS), quality of life, and safety profile.
Results:
No statistically significant differences were observed in the adequate relief response rate between the pinaverium bromide and control group at week 2 (58.3% vs. 62.9%, P = 0.697), week 4 (62.9% vs. 78.1%, P = 0.173), week 6 (64.7% vs. 75.0%, P = 0.363), and week 8 (64.7% vs. 75.0%, P = 0.363). Additionally, there were no significant differences observed in the decline of symptom score between the two groups at week 4 (8.4 ± 7.6 vs. 7.7 ± 7.1, P = 0.702) and week 8 (10.9 ± 8.2 vs. 8.4 ± 7.2, P = 0.196). Similarly, there were no significant differences in terms of quality of life between the two groups. Adverse event rates were also comparable between the two groups.
Conclusion:
Pinaverium bromide was found to be safe in the treatment of refractory dyspepsia, but it did not demonstrate a significant benefit in improving symptoms.
100 项与 匹维溴铵 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 胃痉挛 | 中国 | - | - |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 脓毒症 | 临床前 | 中国 | 2024-01-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | 憲艱遞築壓鬱築積鏇獵(衊憲艱構鬱製鬱觸糧夢) = 糧鏇糧壓襯製觸壓鏇衊 構選淵齋築鹽繭窪廠鏇 (襯鏇鏇膚願鹽觸艱廠範 ) | - | 2014-10-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用